NCT04514458: PROMPT-HF

Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure

Completed NA Results posted Last updated 1 July 2025

What this trial tests

NA trial testing Best practice alert for the notification of patient HFrEF and recommended evidence-based therapies (NO drugs are being administered in this trial) in Heart Failure With Reduced Ejection Fraction in 1,410 participants. Completed in 20 October 2022.

Timeline

25 January 2021

Primary endpoint
20 November 2021

20 October 2022

Quick facts

Lead sponsor	Yale University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	supportive care
Enrollment	1,410
Start date	25 January 2021
Primary completion	20 November 2021
Estimated completion	20 October 2022
Sites	1 location across United States

Drugs / interventions tested

• Best practice alert for the notification of patient HFrEF and recommended evidence-based therapies (NO drugs are being administered in this trial)

Conditions studied

• Heart Failure With Reduced Ejection Fraction — all drugs for Heart Failure With Reduced Ejection Fraction →

Sponsor

Yale University

Who can join

18 and older, any sex, with Heart Failure With Reduced Ejection Fraction. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Percentage of Patients With Heart Failure With Reduced Ejection Fraction (HFrEF) With an Increase in Prescribed HFrEF Therapy Primary · Assessed from the date of randomization to 30 days post-randomization

Assessed as an increase in the number of prescribed targeted evidence-based therapies for HFrEF, including beta-blockers, ACEi, ARBs, ARNIs, MRAs, and SGLT2is.

Group	Value	95% CI
EHR-based Alert	176
Usual Care	117

Percentage of Patients on Beta Blockers Secondary · Assessed from the date of randomization to 30 days post-randomization

Assessed as the number of patients with prescribed beta blockers

Group	Value	95% CI
EHR-based Alert	606
Usual Care	521

Percentage of Patients on ACE Inhibitors Secondary · Assessed from the date of randomization to 30 days post-randomization

Assessed as the number of patients with a prescribed ACEi

Group	Value	95% CI
EHR-based Alert	83
Usual Care	92

Percentage of Patients on ARBs Secondary · Assessed from the date of randomization to 30 days post-randomization

Assessed as the number of patients with a prescribed ARB

Group	Value	95% CI
EHR-based Alert	111
Usual Care	85

Percentage of Patients on ARNIs Secondary · Assessed from the date of randomization to 30 days post-randomization

Assessed as the number of patients with a prescribed ARNI

Group	Value	95% CI
EHR-based Alert	334
Usual Care	285

Percentage of Patients on MRAs Secondary · Assessed from the date of randomization to 30 days post-randomization

Assessed as the number of patients with a prescribed MRA

Group	Value	95% CI
EHR-based Alert	232
Usual Care	203

Percentage of Patients on SGLT2 Inhibitors Secondary · Assessed from the date of randomization to 30 days post-randomization

Assessed as the number of patients with a prescribed SGLT2i

Group	Value	95% CI
EHR-based Alert	144
Usual Care	103

Rate of One-year All-cause Mortality Secondary · Assessed from the date of randomization to the date of death from any cause, up to 365 days post-randomization

Assessed as the number of patients who expired from randomization up to one year from any cause.

Group	Value	95% CI
EHR-based Alert	75
Usual Care	68

Rate of 30-day Hospital Admission Secondary · Assessed from the date of randomization to the date of hospital admission, up to 30 days post-randomization

Number of participants with a hospitalization within 30 days of randomization

Group	Value	95% CI
EHR-based Alert	47
Usual Care	63

Rate of 30-day All-cause Emergency Department Visits Secondary · Assessed from the date of randomization to the date of ED/ER admission, up to 30 days post-randomization

Number of participants with an emergency department visit within 30 days of randomization.

Group	Value	95% CI
EHR-based Alert	86
Usual Care	77

Sponsor's own description

A randomized controlled trial to compare the efficacy of an electronic health record-based alert informing providers about evidence-based medications for HFrEF versus usual care (no alert) in outpatient clinics across a single health system.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

1. Electronic Alerts to Improve Heart Failure Therapy in Outpatient Practice: A Cluster Randomized Trial.
   Ghazi L, Yamamoto Y, Riello RJ, Coronel-Moreno C, et al · · 2022 · cited 155× · PMID 35385798 · DOI 10.1016/j.jacc.2022.03.338
2. Virtual Care Team Guided Management of Patients With Heart Failure During Hospitalization.
   Bhatt AS, Varshney AS, Moscone A, Claggett BL, et al · · 2023 · cited 49× · PMID 36889612 · DOI 10.1016/j.jacc.2023.02.029
3. Rationale and design of a cluster-randomized pragmatic trial aimed at improving use of guideline directed medical therapy in outpatients with heart failure: PRagmatic trial of messaging to providers about treatment of heart failure (PROMPT-HF).
   Ghazi L, Desai NR, Simonov M, Yamamoto Y, et al · · 2022 · cited 12× · PMID 34808104 · DOI 10.1016/j.ahj.2021.11.010